ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. (SPRY) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · SPRY · as of Sep 30, 2025
Ownership Breakdown
200
Institutional Holders
▲ 5 vs Q2
$840.44M
Total Inst. Value
▼ $634.59M vs Q2
99.30M
Shares Outstanding
freeFloat 63.11%
83.63M
13F Shares Held
▼ 888,415 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
SPRY largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
RA CAPITAL MANAGEMENT, L.P. pharmaceutical preparations | 10.86M | 11.04% | 11.04% | $109.15B | Nov 14, 2025 | — held |
ORBIMED ADVISORS LLC pharmaceutical preparations | 8.29M | 8.43% | 8.43% | $83.30B | Nov 14, 2025 | — held |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) pharmaceutical preparations | 7.50M | 7.63% | 7.63% | $75.41B | Nov 14, 2025 | ▼ 2.22M |
BLACKROCK, INC. pharmaceutical preparations | 4.83M | 4.91% | 4.91% | $48.55B | Nov 12, 2025 | ▲ 407.9K |
RUBRIC CAPITAL MANAGEMENT LP pharmaceutical preparations | 4.50M | 4.57% | 4.57% | $45.23B | Nov 14, 2025 | ▲ 3.21M |
SR ONE CAPITAL MANAGEMENT, LP pharmaceutical preparations | 4.01M | 4.08% | 4.08% | $40.33B | Nov 12, 2025 | — held |
VANGUARD GROUP INC pharmaceutical preparations | 3.50M | 3.56% | 3.56% | $35.18B | Nov 7, 2025 | ▲ 237.6K |
ABRDN PLC pharmaceutical preparations | 3.10M | 3.15% | 3.15% | $31.13B | Nov 7, 2025 | ▲ 1.59M |
STATE STREET CORP pharmaceutical preparations | 2.90M | 2.94% | 2.94% | $29.10B | Nov 14, 2025 | ▲ 700.8K |
ALLIANCEBERNSTEIN L.P. pharmaceutical preparations | 2.64M | 2.69% | 2.69% | $26.55B | Nov 14, 2025 | ▼ 1.18M |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
23
Increased
+11.36M shares10
New Positions
first time holders13
Decreased
−6.31M shares0
Sold Out
fully exitedNet shares change (top 50)
+5.05M
+11.36M / −6.31M
Net new holders
+20
10 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
SPRY insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Scott Kathleen D. Chief Financial Officer | Jan 2, 2026 | Award | 240,000 | $11.49 | $2.76M | 240.0K | Form 4 ↗ |
Karas Eric Chief Commercial Officer | Jan 2, 2026 | Award | 240,000 | $11.49 | $2.76M | 240.0K | Form 4 ↗ |
Fitzpatrick Alexander A Chief Legal Officer | Jan 2, 2026 | Award | 240,000 | $11.49 | $2.76M | 240.0K | Form 4 ↗ |
Dorsey Brian Chief Operating Officer | Jan 2, 2026 | Award | 240,000 | $11.49 | $2.76M | 240.0K | Form 4 ↗ |
Chakma Justin Chief Business Officer | Jan 2, 2026 | Award | 240,000 | $11.49 | $2.76M | 240.0K | Form 4 ↗ |
Tanimoto Sarina CHIEF MEDICAL OFFICER | Jan 2, 2026 | Award | 875,000 | $11.49 | $10.05M | 875.0K | Form 4 ↗ |
Tanimoto Sarina CHIEF MEDICAL OFFICER | Jan 2, 2026 | Award | 240,000 | $11.49 | $2.76M | 240.0K | Form 4 ↗ |
Lowenthal Richard E PRESIDENT AND CEO | Jan 2, 2026 | Award | 875,000 | $11.49 | $10.05M | 875.0K | Form 4 ↗ |
Lowenthal Richard E PRESIDENT AND CEO | Jan 2, 2026 | Award | 240,000 | $11.49 | $2.76M | 240.0K | Form 4 ↗ |
Dorsey Brian Chief Operating Officer | Nov 13, 2025 | Sale | 21,828 | $8.71 | $190.0K | 10.8K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
ARS Pharmaceuticals, Inc. (SPRY) is primarily owned by institutional investors, who hold approximately 84.2% of total shares outstanding. Company insiders own approximately 36.89%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of ARS Pharmaceuticals, Inc. is RA CAPITAL MANAGEMENT, L.P., holding approximately 10.86 million shares — equal to 11.04% of outstanding shares — as of September 30, 2025.
A total of 200 institutional investors currently hold SPRY stock, with a combined institutional value of approximately $840,436,328 as of the most recent 13F filing period.
Frequently asked questions
SPRY ownershipARS Pharmaceuticals, Inc. (SPRY) is primarily owned by institutional investors, who hold approximately 84.2% of shares. The largest shareholder is RA CAPITAL MANAGEMENT, L.P. with a 11.04% stake. Company insiders hold 36.89%. Data sourced from SEC Form 13F as of September 30, 2025.